Recent

% | $
Quotes you view appear here for quick access.

OXiGENE, Inc. Message Board

  • kz_for_u kz_for_u Sep 2, 2011 7:20 PM Flag

    Why insiders would own 39% of shares?

    Do they know some thing?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • One could also ask why institutions own so few shares compared to other biotechs. Do they know something? Remember, much of mgmt's shares were either aquired years ago or as options. The institutional holdings should have you scratching your head.

    • I thought they owned over 60% of the shares?

    • Symphony Capital has invested $40M in this company!

      Ask yourself what they will do with a company will $14M in cash, no debt, one late stage VDA drug and one second generation VDA drug in early stage, patents/rights and hardly no staff!

      Cash is sufficient for current operation into 2013 now after the staff reduction.

      My take is:

      -Big pharma licensing-deal
      or
      -Take over bid
      or
      -Financial crisis hibernation pending clinical data release!

      • 1 Reply to mid_swe
      • This is the letter from the CEO! Posted by Gunter at VCW board in Sweden!


        "One of our tasks now is to finalize clear development plans that provide the greatest likelihood of success, not only clinically, but commercially for our later-stage assets"

        http://www.oxigene.com/files/2011_Letter_from_CEO.pdf

        Finally, the OXiGENE team spent agreat deal of time at ASCO meeting with potential partners for our clinical programs. The meetings were very productive, and ranged from talks with specialists interested in orphan drug marketing, to regional firms looking to enter the oncology space, to global pharmaceutical companies interested in finding a new later-phase addition to their oncology franchise. With data from two randomized controlled studies and worldwide rights available for license, we believe that ZYBRESTAT is now an asset uniquely
        suited for collaboration. We intend to take advantage of the interest shown in our VDA assets and continue to advance these ongoing discussions. Overall, I believe our ASCO experience in 2011 was agreat success. The data we presented
        and the discussions we participated in reinforced our belief that our VDA assets are backed by a substantial and growing body of data that clearly suggests their safety and activity, and that there is significant interest from potential partners. One of our tasks now is to finalize clear development plans that provide the greatest likelihood of success, not only clinically, but commercially for our later-stage assets.

 
OXGN
1.18+0.02(+1.72%)Aug 28 3:59 PMEDT